Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis
Status:
Recruiting
Trial end date:
2022-05-29
Target enrollment:
Participant gender:
Summary
This is a patient-sponsored study that evaluates the safety and efficacy of reduced-intensity
immunoablation followed by a single dose autologous hematopoetic stem cell transplantation in
patients diagnosed with multiple sclerosis. Patients are followed-up after 1 month, 3 months,
6 months and 12 months post-transplantation.